Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25480265 | 0.88 | OPRM1 (0.36) | HRH3TLR9TLR8TLR7 | |
| SCHEMBL22520631 | 0.88 | HRH3 (0.35) | HRH3TLR9TLR8TLR7ACHE | |
| SCHEMBL24233214 | 0.86 | HRH3 (0.35) | HRH3TLR9TLR8TLR7ACHE | |
| SCHEMBL24475299 | 0.83 | HRH3 (0.35) | HRH3TLR9TLR8TLR7 | |
| SCHEMBL24233213 | 0.82 | TSHR (0.36) | HRH3TLR9TLR8TLR7 | |
| SCHEMBL24475333 | 0.82 | TSHR (0.36) | HRH3TLR9TLR8TLR7 | |
| SCHEMBL24475321 | 0.81 | HRH3 (0.32) | HRH3 | |
| SCHEMBL22520769 | 0.81 | CHRM5 (0.43) | HRH3TLR9TLR8TLR7ACHE | |
| SCHEMBL24671071 | 0.79 | OPRM1 (0.35) | HRH3 | |
| SCHEMBL14453909 | 0.79 | CHRM5 (0.41) | HRH3TLR9TLR8TLR7ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA UK LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ESR1, GPER1, ESRRG | HRH3 1546/4885TLR9 3198/4885TLR8 2494/4885 |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | HRH3 3926/4885TLR9 4768/4885TLR8 4521/4885 |
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | HRH3 3236/4885TLR9 2903/4885TLR8 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.